FDA Grants Mirvetuximab Full Approval for Ovarian Cancer

Mirvetuximab soravtansine-gynx (Elahere) is approved for patients with folate receptor–alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/fda-grants-mirvetuximab-full-approval-ovarian-cancer-2024a10005m0?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?